SCHEMBL2006324

SCHEMBL2006324

N#Cc1cc(O)c2cnn(-c3ccc(OCc4ccccc4)c(F)c3)c2c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
S1PR5 Q9H228 1/20 0.36
XDH P47989 1/20 0.36
MAPK14 Q16539 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
MAOB P27338 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2005087 0.89 MAPK14 (0.40) MAPTTSHRRECQLNPSR1S1PR5
SCHEMBL14085559 0.89 MAPT (0.41) MAPTTSHRRECQLNPSR1S1PR5
SCHEMBL2005406 0.88 FFAR4 (0.38) MAPTTSHRRECQLNPSR1GABRG2
SCHEMBL2004763 0.87 S1PR5 (0.39) MAPTTSHRS1PR5MAPK14ALDH1A1
SCHEMBL2013480 0.85 MRGPRX4 (0.40) MAPTTSHRS1PR5MAPK14MAOB
SCHEMBL2006708 0.85 MRGPRX4 (0.40) MAPTTSHRS1PR5MAPK14POLB
SCHEMBL2009960 0.84 ERN1 (0.41) MAPTNPSR1S1PR5MAPK14MAOB
SCHEMBL2003916 0.84 S1PR5 (0.40) MAPTTSHRS1PR5MAPK14ALDH1A1
SCHEMBL12572463 0.83 S1PR5 (0.36) MAPTTSHRS1PR5MAPK14ALDH1A1
SCHEMBL1013393 0.82 S1PR5 (0.37) S1PR5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB MAPT 2061/4885TSHR 462/4885RECQL 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.